Aggregated from the cited literature below. We summarize sources — we don't author claims.
Research literature describes tesamorelin as a growth hormone–releasing factor (growth hormone-releasing hormone) analogue that is FDA-approved for reducing excess abdominal fat in people with HIV-associated lipodystrophy, with clinical studies reporting effects on visceral fat and related body-composition outcomes in that indication. Orthopaedic/sports-medicine reviews note a lack of supporting orthopaedic evidence for tesamorelin and identify broader gaps in clinical evidence for “injectable peptide therapy” in musculoskeletal contexts.
Mechanism (as reported)
A review reported that tesamorelin is a synthetic analogue of growth hormone-releasing hormone (growth hormone-releasing factor) that stimulates synthesis and release of endogenous growth hormone. (PMIDs: 22050344, 21668043) Another orthopaedics-focused review described growth hormone secretagogues including tesamorelin as activating IGF-1 signaling and satellite cell repair in the context of musculoskeletal relevance. (PMID: 41490200)
Key findings (each cites a source)
Tesamorelin is described as the only FDA-approved therapy for the reduction of excess abdominal fat in people with HIV-associated lipodystrophy. (PMIDs: 21283099, 22050344, 21668043, 38905488) [PMID 21283099, 22050344, 21668043, 38905488]
Orthopaedic evidence reviews reported that tesamorelin has no supporting orthopaedic evidence. (PMID: 41476424) [PMID 41476424]
A randomized double-blind trial analysis in people with HIV on integrase inhibitor–based regimens reported tesamorelin produced significant declines in visceral fat, hepatic fat, and trunk-to-appendicular fat ratio compared with placebo at 12 months, with similar frequency of adverse events between groups and no exacerbation of glycemic control as reported by the analysis. (PMID: 38905488) [PMID 38905488]
A review of tesamorelin in HIV-associated lipodystrophy described two 26-week, well-designed clinical trials as reporting that tesamorelin reduced visceral adipose tissue, without affecting subcutaneous adipose tissue to a clinically significant extent; it further described that continued therapy maintained VAT reduction through week 52, while discontinuation resulted in VAT reaccumulation. (PMIDs: 22050344, 21668043) [PMID 22050344, 21668043]
Reviews in HIV-associated lipodystrophy described tesamorelin as generally well tolerated over 26 weeks, with treatment-emergent serious adverse events occurring in <4% of patients, and most serious events described as injection-site reactions or events known to be associated with growth hormone therapy (e.g., arthralgia, headache, peripheral edema). (PMIDs: 22050344, 21668043) [PMID 22050344, 21668043]
An orthopaedics/sports-medicine review described peptide therapy as often having limited or missing clinical evidence and stated that information regarding indications, dosing, frequency, and duration remains unknown, including in the context of peptides such as tesamorelin. (PMID: 41476424) [PMID 41476424]
An orthopaedics-focused review described growth hormone secretagogues (including tesamorelin) as activating IGF-1 signaling and satellite cell repair, while also emphasizing the lack of clinical trials. (PMID: 41490200) [PMID 41490200]
A narrative review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance included tesamorelin among prominent peptides marketed to patients and stated that rigorous human safety data are scarce for many unapproved peptides. (PMID: 41966639) [PMID 41966639]
Vendor test rankings (60)
Vendors ranked by their independent third-party test grade for Tesamorelin, attributed to Finnrick. The grade is their verdict, not ours.
Real third-party HPLC results aggregated from Peptigrity, each attributed to the lab that ran it — average purity 99.4% across 440 tests. Not our verdict.
O'Neal R · BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation · 2010 · PMID 21591600
FAQ
What is Tesamorelin?
Tesamorelin (TH9507, MQG94M5EEO, 218949-48-5) is classified under ghrh analogs, an FDA-approved drug. Research goals associated with it include metabolic & weight, gh axis support.
Is Tesamorelin FDA-approved?
Yes — Tesamorelin is approved by the FDA (marketed as TH9507, MQG94M5EEO).
What does the research on Tesamorelin say?
peptideone aggregates 10 references from PubMed for Tesamorelin. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.